Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid

  1. Chapman, M.J.
  2. Zamorano, J.L.
  3. Parhofer, K.G.
Zeitschrift:
Pharmacology and Therapeutics

ISSN: 1879-016X,  0163-7258

Datum der Publikation: 2022

Ausgabe: 237

Art: Rezension

DOI: 10.1016/J.PHARMTHERA.2022.108172 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus